Gilead Sciences, Inc. (Nasdaq: GILD) has announced the upcoming presentation of over 40 HIV research studies at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The research includes late-breaking findings, with seven oral presentations, showcasing Gilead’s comprehensive portfolio and pipeline aimed at advancing HIV treatment and prevention strategies.
“We are excited to present new data from our extensive HIV portfolio, reaffirming our commitment to ending the epidemic through continuous scientific innovation,” said Dr. Jared Baeten, Senior Vice President and Virology Therapeutic Area Head at Gilead. “The breadth of our work at HIV Glasgow 2024 highlights our dedication to person-centered care and driving transformative change in HIV research.”
Key Areas of Focus at HIV Glasgow 2024
HIV Prevention Research
One of the major highlights will be a late-breaking oral presentation on the PURPOSE 2 trial, a Phase 3 study evaluating Gilead’s lenacapavir as a twice-yearly HIV prevention option. This trial, focused on a diverse range of populations, is set to provide new insights into the potential of lenacapavir as the first long-acting, injectable PrEP option for HIV prevention.
Other prevention-related presentations will include:
- A systematic review and meta-analysis of real-world data mapping HIV prevalence against PrEP uptake.
- Health economic data on the impact of PrEP in France.
- Data from a study on same-day PrEP initiation in a Canadian clinic.
HIV Treatment Research
Gilead will present several studies on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), focusing on its long-term effectiveness in patients with common comorbidities. Other key treatment research includes:
- Biktarvy’s role in managing co-existing health conditions, with four-year outcomes from the BICSTaR study.
- Three-year data from the ALLIANCE study evaluating Biktarvy in adults with both HIV and hepatitis B.
- Investigational treatment combinations, including lenacapavir and bictegravir, and lenacapavir with islatravir as a once-weekly regimen.
Additional research will evaluate lenacapavir in combination with teropavimab and zinlirvimab, as well as the investigational GS-1720 integrase inhibitor in combination with GS-4182.
Pipeline Innovations
Several late-breaking studies will explore the potential of lenacapavir in new long-acting HIV treatment regimens, including:
- A combination with broadly neutralizing antibodies as a twice-yearly treatment option.
- A once-weekly regimen combining lenacapavir and islatravir.
Other pipeline data will include pharmacokinetic and resistance analyses of GS-1720, as well as clinical outcomes from the ARTISTRY-1 trial investigating regimen switches to lenacapavir and bictegravir.
Research Beyond Treatment: Addressing the Full HIV Care Continuum
In addition to treatment and prevention, Gilead will present a range of studies addressing key issues in HIV care, including:
- A global survey on engagement in HIV care.
- Real-world effectiveness and patient-reported outcomes from Biktarvy-based regimens.
- Insights into the challenges of managing comorbidities in aging people living with HIV.
Important Notes
- Lenacapavir for HIV prevention and its combination with islatravir and bictegravir are investigational and not yet approved.
- Studies involving GS-5423, GS-2872, and GS-1720 are still in early-phase research.
